Uterine fibroids (also called leiomyomas or myomas) in 99% of cases are noncancerous tumors that grow in or on the uterus.
They are made of muscle and fibrous tissue and vary in size: from tiny seedlings to large masses that can distort the uterus.
Most fibroids are benign, meaning they rarely turn cancerous (<1% of cases).
Fibroids may be asymptomatic. When symptoms are present, they can vary in type and severity depending on size, number, and location of the fibroid(s). Common symptoms include:
Abnormal uterine bleeding
Heavy menstrual bleeding, prolonged periods, spotting, or bleeding between cycles
Anemia and related effects
Iron deficiency anemia, often leading to fatigue, weakness, or shortness of breath
Pelvic discomfort and pain
Pelvic pain, lower back pain, menstrual cramps, or a persistent sense of pressure
Abdominal changes
Bloating, visible swelling, or a feeling of fullness in the lower abdomen
Urinary and bowel symptoms
Frequent urination, difficulty emptying the bladder, or constipation
Reproductive and sexual health concerns
Pain or discomfort during intercourse, infertility, or pregnancy complications
Radiating pain
Leg pain or discomfort due to pressure on surrounding nerves
General wellbeing
Fatigue and reduced quality of life, including emotional distress
Fibroids are extremely common, with estimates suggesting that up to 70 to 80 percent of women will develop them by age 50, often without noticeable symptoms. They are most commonly diagnosed between the ages of 30 and 49, although they can occur at any time during the reproductive years.
Several factors are associated with a higher likelihood of developing fibroids, including:
Family history and genetic predisposition
Higher body weight and obesity
Early onset of menstruation
Vitamin D deficiency
African-American race, with an earlier onset and often more severe disease
Pregnancy is associated with a reduced risk of developing fibroids. Women who have given birth are less likely to develop them, and this protective effect appears to increase with each additional pregnancy.
Fibroids are the leading cause of hysterectomy worldwide.
They affect millions of women’s daily lives, causing chronic pain, missed work, emotional strain, and fertility challenges.
About 26 million women in the U.S. have fibroids
24% report fibroids affect career potential; 28% reported missing work due to symptoms.
Despite prevalence, fibroids remain under-discussed, under-researched, and under-funded.
Location: Develop within the muscular wall of the uterus
Key point: Most common type of fibroid
Symptoms: Heavy menstrual bleeding, pelvic pain, and pressure, especially as they enlarge
Location: Form just beneath the uterine lining (endometrium) and may extend into the uterine cavity
Key point: Even small fibroids can cause significant symptoms
Symptoms: Heavy or prolonged menstrual bleeding, fertility challenges, and increased risk of miscarriage
Location: Grow on the outer surface of the uterus and expand outward
Key point: Less likely to affect menstrual bleeding
Symptoms: Pressure on nearby organs, leading to frequent urination, constipation, or lower back pain
Location: Attached to the uterus by a thin stalk, either inside or outside the uterus
Key point: Risk of torsion (twisting), which can cause acute pain
Symptoms: Sudden or localized pain, as well as pressure symptoms depending on size and position
Location: Develop in the cervix, the lower portion of the uterus that connects to the vagina
Key point: Relatively rare
Symptoms: Urinary symptoms, pain during intercourse, or complications with labor and delivery
6. Calcified Fibroids
Definition: Fibroids that have undergone degeneration and developed calcium deposits
Key point: Typically represent a later stage of fibroid life cycle and are no longer actively growing
Symptoms: Often asymptomatic, but may cause discomfort or pressure if large or poorly positioned
1. Watchful Waiting (Monitoring)
For women with no or mild symptoms.
Fibroids may shrink after menopause.
Regular ultrasounds and check-ups.
2. Medications
Hormonal treatments help control symptoms, but they do not cure fibroids.
GnRH agonists (e.g., Lupron) → can shrink fibroids temporarily and are often used before surgery.
GnRH antagonists (newer oral medications):
Relugolix combination therapy (e.g., Myfembree, Ryeqo) → oral GnRH antagonist combined with estrogen and progestin; helps reduce heavy menstrual bleeding and other fibroid-related symptoms.
Linzagolix (e.g., Yselty) → oral GnRH antagonist used for moderate to severe fibroid symptoms; reduces heavy bleeding and can be used with or without add-back hormone therapy.
Elagolix combination therapy (e.g., Oriahnn) → helps reduce heavy menstrual bleeding associated with fibroids.
Progestin-releasing IUD → reduces heavy bleeding but does not shrink fibroids.
Oral contraceptives → help control bleeding but do not reduce fibroid size.
Tranexamic acid (e.g., Lysteda) → non-hormonal medication taken during menstruation that helps reduce heavy bleeding.
Iron supplements → used to treat or prevent anemia caused by heavy menstrual bleeding.
3. Minimally Invasive Procedures
Uterine artery embolization, UAE or UFE → blocks blood flow to fibroids, causing them to shrink.
MRI-guided focused ultrasound surgery, FUS → noninvasive treatment that uses high-intensity ultrasound to destroy fibroid tissue without an incision.
Radiofrequency ablation → uses heat energy to destroy fibroid tissue and shrink fibroids over time. This includes laparoscopic radiofrequency ablation, such as Acessa, and transcervical radiofrequency ablation, TCRF, such as Sonata, which is performed through the cervix without abdominal incisions.
4. Surgical Options
Myomectomy (removal of fibroids, uterus preserved):
Hysteroscopic → through the vagina and cervix, for submucosal fibroids.
Laparoscopic or robotic → through small abdominal incisions, for selected fibroids depending on size, number, and location.
Abdominal → open surgery for large, multiple, or complex fibroids.
Important: Fibroids can recur after myomectomy.
Hysterectomy (removal of uterus):
Definitive treatment for fibroids, with no recurrence.
Ends the ability to carry a pregnancy.
Can be performed vaginally, laparoscopically, robotically, or abdominally, depending on the case.
Alternative / Complementary Approaches
Not cures, but may help with symptoms, inflammation, or overall health. Effectiveness varies, and evidence is limited or mixed.
1. Lifestyle & Natural Supports
Dietary changes → higher intake of fruits, vegetables, and whole grains is associated with lower fibroid risk; high intake of red meat and processed foods is associated with higher risk.
Exercise and weight management → may help regulate estrogen levels and reduce overall risk, though direct impact on existing fibroids is not clearly established.
Stress reduction → yoga, meditation, and breathing practices may improve overall well-being and symptom perception, but do not directly treat fibroids.
2. Supplements & Herbal Supports (consult a doctor before use)
Green tea extract (EGCG) → some clinical evidence suggests a reduction in fibroid volume and improvement in symptoms, but data is still limited, and dosing is not standardized.
Vitamin D → deficiency is associated with higher fibroid risk; supplementation may have a protective role, though evidence for shrinking existing fibroids is not conclusive.
Turmeric or curcumin → anti-inflammatory properties; evidence is mostly preclinical and not sufficient to confirm clinical benefit for fibroids.
Milk thistle → supports liver function; no strong clinical evidence for fibroid treatment.
Omega-3 fatty acids → anti-inflammatory effects; may support overall health, but no direct evidence for fibroid reduction.
3. Traditional / Integrative Medicine
Acupuncture → may help reduce pelvic pain and improve quality of life; does not shrink fibroids.
Chinese herbal medicine → used for symptom management and menstrual regulation; evidence varies, and formulations are not standardized.
Ayurveda → includes herbal therapies and lifestyle approaches aimed at balance; no strong clinical evidence for fibroid reduction.
Resources used
American College of Obstetricians and Gynecologists. "Uterine Fibroids." ACOG.
https://www.acog.org/womens-health/faqs/uterine-fibroids
Stewart EA, Laughlin-Tommaso SK, Catherino WH, et al. "Uterine Fibroids." Nature Reviews Disease Primers. 2016. PubMed.
https://pubmed.ncbi.nlm.nih.gov/27335259/
Bulun SE. "Uterine Fibroids." New England Journal of Medicine. 2013. PubMed.
https://pubmed.ncbi.nlm.nih.gov/23425105/
Baird DD, Dunson DB, Hill MC, et al. "High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence." American Journal of Obstetrics and Gynecology. 2003. PubMed.
https://pubmed.ncbi.nlm.nih.gov/12548202/
Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. "Epidemiology of Uterine Fibroids: A Systematic Review." BJOG. 2017. PubMed.
https://pubmed.ncbi.nlm.nih.gov/28296146/
Wise LA, Laughlin-Tommaso SK. "Epidemiology of Uterine Fibroids." Obstetrics and Gynecology Clinics of North America. 2016. PubMed.
https://pubmed.ncbi.nlm.nih.gov/27521872/
Cardozo ER, Clark AD, Banks NK, et al. "The Estimated Annual Cost of Uterine Leiomyomata in the United States." American Journal of Obstetrics and Gynecology. 2012. PubMed.
https://pubmed.ncbi.nlm.nih.gov/22244472/
Borah BJ, Nicholson WK, Bradley L, Stewart EA. "The Impact of Uterine Leiomyomas: A National Survey of Affected Women." American Journal of Obstetrics and Gynecology. 2013. PubMed.
https://pubmed.ncbi.nlm.nih.gov/23578907/
Hartmann KE, et al. "Management of Uterine Fibroids." Agency for Healthcare Research and Quality.
https://www.ncbi.nlm.nih.gov/books/NBK537747/
Al-Hendy A, Lukes AS, Poindexter AN, et al. "Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy." New England Journal of Medicine. 2021. PubMed.
https://pubmed.ncbi.nlm.nih.gov/33596357/
Schlaff WD, Ackerman RT, Al-Hilli MM, et al. "Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids." New England Journal of Medicine. 2020. PubMed.
https://pubmed.ncbi.nlm.nih.gov/32187469/
Donnez J, Donnez O, Dolmans MM. "Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids." New England Journal of Medicine. 2020. PubMed.
https://pubmed.ncbi.nlm.nih.gov/32966714/
Lethaby A, Puscasiu L, Vollenhoven B. "Preoperative Medical Therapy before Surgery for Uterine Fibroids." Cochrane Database of Systematic Reviews. 2017. PubMed.
https://pubmed.ncbi.nlm.nih.gov/28881015/
Pron G. "Uterine Artery Embolization: Indications and Outcomes." Seminars in Interventional Radiology. 2008. PubMed.
https://pubmed.ncbi.nlm.nih.gov/21326515/
Stewart EA, Rabinovici J, Tempany CMC, et al. "Clinical Outcomes of Focused Ultrasound Surgery for the Treatment of Uterine Fibroids." Fertility and Sterility. 2006. PubMed.
https://pubmed.ncbi.nlm.nih.gov/16595228/
Chudnoff SG, Berman JM, Levine DJ, et al. "Outcomes of Radiofrequency Ablation of Uterine Fibroids." Obstetrics and Gynecology. 2013. PubMed.
https://pubmed.ncbi.nlm.nih.gov/23344364/
Berman JM, Guido RS, Garza-Leal JG, et al. "Three-Year Outcome of the SONATA Trial of Transcervical Fibroid Ablation." Journal of Gynecologic Surgery. 2020. PubMed.
https://pubmed.ncbi.nlm.nih.gov/32764212/
Parker WH. "Uterine Myomas: Management." Fertility and Sterility. 2007. PubMed.
https://pubmed.ncbi.nlm.nih.gov/17499748/
Nagata C, Takatsuka N, Kawakami N, Shimizu H. "Association of Diet with the Risk of Uterine Fibroids." Journal of Epidemiology. 2001. PubMed.
https://pubmed.ncbi.nlm.nih.gov/11446471/
Wise LA, Palmer JR, Spiegelman D, et al. "Influence of Body Size and Body Fat Distribution on Risk of Uterine Leiomyomata." Epidemiology. 2005. PubMed.
https://pubmed.ncbi.nlm.nih.gov/16155442/
Roshdy E, Rajaratnam V, Maitra S, Sabry M. "Treatment of Symptomatic Uterine Fibroids with Green Tea Extract." International Journal of Women’s Health. 2013. PubMed.
https://pubmed.ncbi.nlm.nih.gov/24143192/
Ciebiera M, Włodarczyk M, Zgliczyński S, et al. "The Role of Vitamin D in the Pathogenesis of Uterine Fibroids." International Journal of Molecular Sciences. 2018. PubMed.
https://pubmed.ncbi.nlm.nih.gov/29614798/
Hewlings SJ, Kalman DS. "Curcumin: A Review of Its Effects on Human Health." Foods. 2017. PubMed.
https://pubmed.ncbi.nlm.nih.gov/29065496/
Aninye IO, et al. "Uterine Fibroids: Assessing Unmet Needs from Bench to Bedside." F and S Reviews. 2021. PubMed.